We have added Ravidasvir (Ravida®) to the drug interaction checker, in our first addition to the lineup of Direct Acting Antivirals for many years.
Ravidasvir is an NS5A inhibitor approved for use with sofosbuvir, which achieved a 97% cure rate in clinical trials in Malaysia. Ravidasvir is an affordable medication, that will expand access to an HCV cure to low-to-middle-income countries. Ravidasvir does not interact with CYP enzymes but is a P-gp substrate, so coadministration with strong P-gp inducers is contraindicated and coadministration with moderate P-gp inducers is not recommended.
Our thanks to DNDi for providing pharmacokinetic data to assist with writing the drug interactions.
